|
 Previous Article | Table of Contents | Next Article 
Specificity of effector T lymphocytes in autologous graft-versus-host
disease: role of the major histocompatibility complex class II invariant
chain peptide
AD Hess, EC Bright, C Thoburn, GB Vogelsang, RJ Jones and MJ Kennedy
Bone Marrow Transplantation Unit, Oncology Center, The Johns Hopkins
University, Baltimore, MD 21287-8985, USA.
Administration of the immunosuppressive drug cyclosporine after autologous
bone marrow transplantation induces a systemic autoimmune syndrome
resembling graft-versus-host disease (GVHD). This syndrome termed
autologous GVHD has significant antitumor activity. Associated with
autologous GVHD is the development of T lymphocytes that recognize major
histocompatibility complex (MHC) class II determinants, including self. The
present studies attempted to characterize and define the molecular
specificity of the effector T lymphocytes in autologous GVHD induced in
patients with metastatic breast cancer. The results suggest that the
effector cells associated with human autologous GVHD are CD8+ T lymphocytes
expressing the alpha/beta T-cell receptor. Additional studies show that the
effector T cells recognize MHC class II antigens in association with a
peptide from the invariant chain (CLIP). Pretreatment of autologous
lymphoblast target cells with anti-CLIP antibody completely blocked lysis
mediated by autologous GVHD effector T cells. On the other hand, force
loading this peptide markedly enhanced the susceptibility of the target
cells to recognition by the autoreactive T cells. The recognition of the
MHC class II CLIP complex may account for the novel specificity of the
effector T cells associated with human autologous GVHD. Moreover,
identification of the target peptide may allow for the development of novel
immunotherapeutic strategies to enhance the antitumor efficacy of
autologous GVHD.
Volume 89,
Issue 6,
pp. 2203-2209,
03/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. S. Bryson, C. D. Jennings, J. A. Brandon, J. Perez, B. E. Caywood, and A. M. Kaplan
Adoptive transfer of murine syngeneic graft-vs.-host disease by CD4+ T cells
J. Leukoc. Biol.,
December 1, 2007;
82(6):
1393 - 1400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Zenz, M. Ritgen, P. Dreger, A. Krober, T. F. Barth, R. Schlenk, S. Bottcher, M. J. Hallek, M. Kneba, D. Bunjes, et al.
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia
Blood,
September 15, 2006;
108(6):
2127 - 2130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bellemare-Pelletier, J. Tremblay, S. Beaulieu, M.-R. Boulassel, J.-P. Routy, B. Massie, R. Lapointe, and J. Thibodeau
HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing
J. Leukoc. Biol.,
July 1, 2005;
78(1):
95 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Miura, C. J. Thoburn, E. C. Bright, M. L. Phelps, T. Shin, E. C. Matsui, W. H. Matsui, S. Arai, E. J. Fuchs, G. B. Vogelsang, et al.
Association of Foxp3 regulatory gene expression with graft-versus-host disease
Blood,
October 1, 2004;
104(7):
2187 - 2193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Bryson, L. Zhang, S. W. Goes, C. D. Jennings, B. E. Caywood, S. L. Carlson, and A. M. Kaplan
CD4+ T Cells Mediate Murine Syngeneic Graft-versus-Host Disease-Associated Colitis
J. Immunol.,
January 1, 2004;
172(1):
679 - 687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Flanagan, C. D. Jennings, S. W. Goes, B. E. Caywood, R. Gross, A. M. Kaplan, and J. S. Bryson
Nitric oxide participates in the intestinal pathology associated with murine syngeneic graft-versus-host disease
J. Leukoc. Biol.,
October 1, 2002;
72(4):
762 - 768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Miura, C. J. Thoburn, E. C. Bright, W. Chen, S. Nakao, and A. D. Hess
Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD
Blood,
September 18, 2002;
100(7):
2650 - 2658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny
Intensive therapies in follicular non-Hodgkin lymphomas
Blood,
July 30, 2002;
100(4):
1141 - 1152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Miura, C. J. Thoburn, E. C. Bright, M. Sommer, S. Lefell, M. Ueda, S. Nakao, and A. D. Hess
Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD
Blood,
August 1, 2001;
98(3):
868 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Flanagan, C. D. Jennings, and J. S. Bryson
Th1 Cytokines and NK Cells Participate in the Development of Murine Syngeneic Graft-Versus-Host Disease
J. Immunol.,
August 1, 1999;
163(3):
1170 - 1177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Chen, C. Thoburn, and A. D. Hess
Characterization of the Pathogenic Autoreactive T Cells in Cyclosporine-Induced Syngeneic Graft-Versus-Host Disease
J. Immunol.,
December 15, 1998;
161(12):
7040 - 7046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bosshart and R. F. Jarrett
Deficient Major Histocompatibility Complex Class II Antigen Presentation in a Subset of Hodgkin's Disease Tumor Cells
Blood,
October 1, 1998;
92(7):
2252 - 2259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Guillaume, D. B. Rubinstein, and M. Symann
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Blood,
September 1, 1998;
92(5):
1471 - 1490.
[Full Text]
[PDF]
|
|
|
|
|
